Pharmaceutical Executive Daily
New research suggests Ozempic may reduce biological age.
In today's Pharmaceutical Executive Daily, we cover top news in the pharmaceutical and life sciences industry, including:
- FDA approval of Bayer's Lynkuet for menopausal hot flashes
- New research on Ozempic's potential to reduce biological age
- Novartis' $12 billion merger agreement to acquire Avidity Biosciences
The FDA approved Bayer's Lynkuet, a dual neurokinin 1 and 3 receptor antagonist, for treating moderate to severe vasomotor symptoms associated with menopause.
The approval is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
Lynkuet provides a non-hormonal option for patients seeking relief from menopausal symptoms without estrogen exposure.
Author's summary: New research on Ozempic and FDA approval of Lynkuet.
More News
- Vance says troops will be paid as pressure builds to end shutdown
- Al-Nassr 1-2 Al-Ittihad: Report, result and goals as Karim Benzema scores to knock Cristiano Ronaldo's side out of Kings Cup
- Looking back: Local ghost legends
- Charlie Kirk’s accused killer allowed to wear street clothes in court
- Trump administration quietly purges ICE leaders in five cities, including Denver: Sources
- Al Nassr Al-Ittihad Jeddah 28 10 2025 Live Score and Match Summary
- From WNBA Court To Playmate Glam: Check Out Kysre Gondrezick’s Sexiest Photos
- Keurig Dr Pepper Shares Updates For Plan To Split Into 2 Companies
- Lifeway search committee now accepting nominations - The Christian Index
- State Rep. Marcus Wiedower Resigns; Special Election Will Be Called - Flagpole